文献速递瓣膜外科

白蛋白可预测经导管主动脉瓣置换术后1年死亡率

Albumin Is Predictive of 1-Year Mortality After Transcatheter Aortic Valve Replacement.
PubMed 文献 · Ann Thorac Surg · 2018-07-23

单中心470例TAVR患者中,1年死亡63例(13.4%)。STS预测死亡风险模型单独预测1年死亡率能力差(AUC 0.52),仅包含肌少症和全部衰弱标志物的模型显著改善预测能力(AUC 0.61,p=0.05)。白蛋白是唯一与1年死亡风险增加显著相关的衰弱标志物(p=0.03)。

要点

  • STS预测死亡风险模型单独预测TAVR术后1年死亡率能力差(AUC 0.52)。
  • 包含肌少症和全部衰弱标志物的模型预测能力显著优于STS模型(AUC 0.61,p=0.05)。
  • 白蛋白是唯一与1年死亡风险增加显著相关的衰弱标志物(p=0.03)。

核心结论

  • 大多数常用的TAVR术前风险评估对1年死亡率预测能力差。
  • 白蛋白是唯一与较高死亡率相关的衰弱标志物。
  • 未来研究应探讨优化营养状态能否改善TAVR术后结局。

研究设计与样本

  • 单中心评估470例接受TAVR的患者。
  • 衰弱采用4个标志物评估:步速、握力、血清白蛋白和Katz日常生活活动能力。
  • 肌少症以TAVR术前CT测量的腰大肌横截面积表示。
  • 采用4个模型(分别纳入STS预测死亡风险、衰弱或肌少症指标、或两者)预测1年死亡率,以曲线下面积、Hosmer-Lemeshow统计量和校准图评估。

主要发现

  • 1年内共发生63例死亡(13.4%)。
  • STS预测死亡风险模型单独预测1年死亡率能力差(AUC 0.52;95%CI 0.42-0.68)。
  • 仅包含肌少症和全部衰弱标志物的模型(AUC 0.61;95%CI 0.53-0.68)较STS预测死亡风险模型单独预测显著改善预测能力(p=0.05)。
  • 白蛋白是唯一与1年死亡风险增加显著相关的衰弱标志物(p=0.03)。
  • 腰大肌面积作为肌少症替代指标与1年死亡风险增加无显著相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A validated model for predicting 1-year outcomes after transcatheter aortic valve replacement (TAVR) does not exist. TAVR-specific risk models may benefit from frailty markers, and sarcopenia may represent an objective frailty marker. This study assessed the predictive ability of sarcopenia and frailty markers on 1-year mortality after TAVR. METHODS: We evaluated 470 patients undergoing TAVR at a single center. Frailty was assessed using four markers: gait speed, hand grip strength, serum albumin, and Katz activities of daily living. Sarcopenia was measured as the cross-sectional psoas muscle area on pre-TAVR computed tomography. Performance of four models incorporating The Society of Thoracic Surgeons Predicted Risk of Mortality, frailty, or sarcopenia metrics, or both, for predicting 1-year mortality was assessed with area under the curve, Hosmer-Lemeshow statistics, and calibration plots. RESULTS: A total of 63 deaths (13.4%) deaths occurred by 1 year. The Society of Thoracic Surgeons Predicted Risk of Mortality alone was poorly predictive of 1-year mortality (area under the curve, 0.52; 95% confidence interval, 0.42 to 0.68). Only the model including sarcopenia and all frailty markers (area under the curve, 0.61; 95% confidence interval, 0.53 to 0.68) significantly improved predictive ability compared with The Society of Thoracic Surgeons Predicted Risk of Mortality alone (p = 0.05). Albumin was the only frailty marker significantly associated with increased risk for 1-year mortality (p = 0.03). Psoas muscle area, as a surrogate for sarcopenia, was not significantly associated with increased risk for 1-year mortality. CONCLUSIONS: Most of the commonly used pre-TAVR risk assessments are poorly predictive of 1-year mortality. Albumin was the only frailty marker that was associated with higher mortality. Future studies should investigate whether optimization of nutritional status can improve outcomes after TAVR.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Hebeler KR, Baumgarten H, Squiers JJ, et al. Albumin Is Predictive of 1-Year Mortality After Transcatheter Aortic Valve Replacement. Ann Thorac Surg. 2018. PMID: 30048632. doi:10.1016/j.athoracsur.2018.06.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。